A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Public ClinicalTrials.gov record NCT04680052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
Study identification
- NCT ID
- NCT04680052
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 654 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2021 (Actual)
- Primary completion
- Feb 23, 2024 (Actual)
- Completion
- Aug 9, 2028 (Estimated)
- Last update posted
- Sep 4, 2026
2021 – 2028
United States locations
- U.S. sites
- 38
- U.S. states
- 21
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| John Muir Health Clinical Research Center | Concord | California | 94520-2266 | — |
| Marin Cancer Care | Greenbrae | California | 94904 | — |
| The Oncology Institute of Hope and Innovation | Pasadena | California | 91105 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Middlesex Hospital Cancer Center | Middletown | Connecticut | 06457 | — |
| Smilow Cancer Hospital | New Haven | Connecticut | 06510 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| Brcr Medical Center, Inc | Plantation | Florida | 33322 | — |
| Asclepes Research Centers | Weeki Wachee | Florida | 34607 | — |
| Northwest Georgia Oncology Centers,P.C | Marietta | Georgia | 30060 | — |
| Straub Medical Center | Honolulu | Hawaii | 96813 | — |
| Des Moines Oncology Research Association | Des Moines | Iowa | 50309 | — |
| Baptist Health Lexington | Lexington | Kentucky | 40503 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| University of Maryland-Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Cancer Center For Blood Disorders | Bethesda | Maryland | 20817 | — |
| Barbara Ann Karmanos Cancer Hospital | Detroit | Michigan | 48201 | — |
| Metro-Minnesota Community Oncology Reserch Consortium (Mmcorc) | Saint Louis Park | Minnesota | 55416 | — |
| Hattiesburg Clinic Hematology | Hattiesburg | Mississippi | 39401 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Nyu Clinical Cancer Center | New York | New York | 10016 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Integris Cancer Institute | Oklahoma City | Oklahoma | 73142 | — |
| Charleston Hematology Oncology Associates | Charleston | South Carolina | 29414 | — |
| Prisma Health Upstate | Greenville | South Carolina | 29615 | — |
| Prairie Lakes Health Care System, Inc. | Watertown | South Dakota | 57201 | — |
| Texas Oncology-Baylor Charles A. Sammons | Dallas | Texas | 75246 | — |
| The Center For Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Lyndon B Johnson General Hospital | Houston | Texas | 77026 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| Renovatio Clinical | Spring | Texas | 77380 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84107 | — |
| University of Virginia Medical Center | Charlottesville | Virginia | 22908 | — |
| Vista Oncology Inc Ps | Olympia | Washington | 98506 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Washington-Seattle Cancer Care Alliance | Seattle | Washington | 98109-4405 | — |
| Northwest Medical Specialties Pllc | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 223 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04680052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04680052 live on ClinicalTrials.gov.